Capricor Therapeutics, Inc. (CAPR): Operating Cash Flow
-$69.81M
Year ended 2025-12-31
-$104.00M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$69.81M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$40.00M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$25.60M | n/m | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $4.92M | n/m | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | -$16.81M | n/m | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | -$10.05M | n/m | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | -$6.82M | n/m | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | -$13.86M | n/m | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$14.23M | n/m | 2019-03-29, From 2017-01-01 |
| 2016-12-31 | -$14.45M | n/a | 2018-03-22, From 2016-01-01 |
| No annual figure between 2012-12-31 and 2016-12-31. | |||
| 2012-12-31 | -$2.19M | n/m | 2013-06-21, From 2012-01-01 |
| 2011-12-31 | -$4.65M | n/m | 2013-06-21, From 2011-01-01 |
| 2010-12-31 | -$4.32M | n/a | 2012-04-02, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | 2025-12-31 | -$69.81M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $9.57B | +11.8% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $14.16B | -6.8% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $2.45M | +109.7% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $16.81B | +90.7% |
| Pfizer Inc (PFE) | 2025-12-31 | $11.70B | -8.2% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $24.53B | +1.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $16.47B | -23.3% |
Compare CAPR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗